Matches in Nanopublications for { <http://rdf.disgenet.org/nanopublications.trig#NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion type Assertion NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_head.
- NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion description "[Body composition, glucose metabolism, and circulating adipokines (adiponectin (AD), high-molecular weight AD (HMWAD), leptin, vascular endothelial growth factor-A (VEGF-A), monocyte chemotactic protein 1 (MCP1), and thioredoxin (TRX)) were measured in 37 patients with active acromegaly before and after treatment.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_provenance.
- NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion evidence source_evidence_literature NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_provenance.
- NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion SIO_000772 24092547 NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_provenance.
- NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion wasDerivedFrom befree-20140225 NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_provenance.
- NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_assertion wasGeneratedBy ECO_0000203 NP183084.RACOQNnhbMzvM72K-AummL9RxuuEHP22_rukZlCmNC3Bs130_provenance.